Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 977-982

  Wallis, C J D ^a   Cheung, P ^b   Herschorn, S ^a   Saskin, R ^c   Su, J ^c   Klotz, L H ^a   Kulkarni, G S ^d   Lee, Y ^e   Kodama, R T ^a   Narod, S A ^f   Nam, R K ^a  

^a Division of Urology   (Canada)

^b Department of Radiation Oncology ^*  (Canada)

^c Canada   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

propensity score; prostatectomy; prostatic neoplasms; radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; COMORBIDITY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE PROCEDURE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATE CANCER; PROSTATECTOMY; UROLOGICAL PROCEDURE; ADVERSE EFFECTS; COHORT ANALYSIS; KAPLAN MEIER METHOD; ONTARIO; POSTOPERATIVE COMPLICATIONS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; COHORT STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; ONTARIO; POSTOPERATIVE COMPLICATIONS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84925304543     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.54     Document Type: Article

References (22)

1. Austin PC, Daly PA, Tu JV (2002) A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 144(2): 290-296.
2. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ (2001) Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 91(12): 2302-2314.
3. Basaria S, Lieb 2nd J, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS (2002) Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56(6): 779-786.
4. Berrington deGonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12(4): 353-360.
5. Bianco Jr. FJ, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (trifecta). Urology 66(5 Suppl): 83-94.
6. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327): 103-106.
7. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M. R. European Organization for and C. Treatment of (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485): 572-578.
8. Center H. S. R. D. (2005) The Johns Hopkins ACG Case-Mix System Reference Manual Version 7.0. The Johns Hopkins University Bloomberg School of Public Health: Baltimore, MD, USA.
9. Chen AC, Petrylak DP (2004) Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 6(3): 209-215.
10. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T (2009) Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD 6(5): 388-394.
11. Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ (2011) Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 60(6): 1142-1148.
12. Holzbeierlein JM, McLaughlin MD, Thrasher JB (2004) Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14(3): 177-183.
13. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, Deasy JO, Michalski JM, Kallogjeri D, Piccirillo JF, Rabah DM, Yu C, Kattan MW, Stephenson AJ (2012) Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 187(4): 1259-1265.
14. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV (2005) Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43(2): 182-188.
15. Nam RK, Cheung P, Herschorn S, Saskin R, Su J, Klotz LH, Chang M, Kulkarni GS, Lee Y, Kodama RT, Narod SA (2014) Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 15(2): 223-231.
16. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96(18): 1358-1367.
17. Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wiklund P (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348: g1502.
18. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291(11): 1325-1332.
19. Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11): 2388-2399.
20. Thompson Jr. IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. J Am Med Assoc 296(19): 2329-2335.
21. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3): 956-962.
22. Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA (2007) Accuracy of administrative databases in identifying patients with hypertension. Open Med 1(1): e18-e26.